Imaging Prostate Cancer With Technetium-99m Tricarbonyl Finasteride Dithiocarbamate

    March 2018 in “ Journal of labelled compounds & radiopharmaceuticals ”
    Syed Qaiser Shah, Gul‐e‐Raana, Ghias Uddin
    Studysummary In this study, researchers developed a new prostate cancer imaging agent, a [99m Tc]tricarbonyl complex derived from finasteride, which demonstrated high radiochemical purity and significant uptake in the prostate of a rat model, suggesting its potential for noninvasive prostate cancer imaging.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on analyticalsciencejournals.onlinelibrary.wiley.com →
    Discuss this study in the Community →

    Research cited in this study 2

    1. Effect of 1 mg/Day Finasteride on Concentrations of Serum Prostate-Specific Antigen in Men With Androgenic Alopecia: A Randomized Controlled Trial Lancet Oncology · 2006
    2. The Long-Term Effect of Doxazosin, Finasteride, and Combination Therapy on the Clinical Progression of Benign Prostatic Hyperplasia The New England Journal of Medicine · 2003

    Related research 1

    1. Imaging Prostate Cancer With Technetium-99m Tricarbonyl Finasteride Dithiocarbamate Journal of labelled compounds & radiopharmaceuticals · 2018